Eurofins MWG Operon and Genomatix Developed Most Complete Human Exome Array
Joint Services Offered for Human Exome Targeted Re-Sequencing Based on Roche NimbleGen Format
"We are pleased to offer this comprehensive service for human exome capture, targeted resequencing and data interpretation. The development of the new exome array was necessary, as currently available versions of human wholeexome capture products do not include or do not efficiently capture many medically relevant genes, so that researchers might miss important information." says Bruno Poddevin, Eurofins Senior Vice President, Genomic Services.
Klaus May, Chief Business Officer of Genomatix, says: "Based on the latest human reference genome sequence hg19/NCBI37/GRCh37 and our proprietary ElDorado extended genome annotation 02-2010 we developed a human exome with 282,363 target regions, representing 240,402 exonic regions. We included splice sites and added 83,246 proximal promoter regions plus 678 microRNAs in order to allow the researcher to obtain the most comprehensive picture that exon capturing technology allows today. The combined expertise of Eurofins and Genomatix enables us to offer the most advanced whole exome analysis service available to date."
A very recent comparison study by Kevin Jacobs, Director of Scientific Operations of Bioinformatics at the National Cancer Institute, presented at the June "Beyond Sequencing Conference" in San Francisco, showed that between 17 percent and 23 percent of human coding sequences are not targeted by current exome capturing systems, missing out several medically important genes.
The new proprietary exome is filling that gap. It is contained on two 2.1M NimbleGen arrays and is usually sequenced with two channels of a GA IIx run with 108bp chemistry.
Genomatix Software GmbH is a computational biology company headquartered in Munich, Germany with a seat of business in Ann Arbor, MI, U.S.A. Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation. More than a decade of developments in computational and systems biology has put Genomatix into the position to have a complete analysis pipeline in place at the arrival of next generation sequencing technology. Genomatix has published more than 180 peer reviewed scientific papers with more than 5,000 citations. Over 35,000 researchers worldwide currently apply Genomatix tools and databases. For further information, please visit www.genomatix.de
About Eurofins Genomics GmbH
Eurofins MWG Operon, a member of the Eurofins Group with major offices and production facilities in Europe, the United States, and Asia, is an international provider of DNA sequencing services, DNA synthesis products and bioinformatic services for academic and industrial research. As one of the first service providers for next generation sequencing, Eurofins MWG Operon has established profound knowhow and proprietary protocols to cover a broad range of applications. The company's strength is its strong customer orientation, fast service, and high quality. For further information, please visit our website at: www.eurofinsdna.com